Trading Update

RNS Number : 6024J
MaxCyte, Inc.
23 December 2020


 MaxCyte to exceed 2020 Full Year market expectations 


Gaithersburg, Maryland - 23 December 2020:  MaxCyte (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today announces an update on trading for the full year 2020 and progress of the CARMA programme.


Based on ongoing momentum in transformational cell therapies and milestone payments from growth in clinical and commercial license partnerships, MaxCyte expects  financial results to be ahead of market expectations for the full-year in the core life sciences business (before CARMA costs). A more detailed trading update will be announced the week of 18 January 2021.


MaxCyte continues to work with Locust Walk on the strategy and future funding of the Group's CARMA business, and enrolment and dosing in the existing CARMA no-preconditioning MCY-M11 clinical study is continuing well. The Company will provide a further update in January.


MaxCyte President & CEO, Doug Doerfler, said: "We have seen sustained strong growth in our core life sciences business as demand for our next generation gene and cell therapy enabling products continues to expand internationally, despite the issues that COVID-19 has placed around the globe.  MaxCyte continues to be uniquely positioned to capitalise on the rapidly growing cell therapy market."


About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit .


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).




MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Amanda Murphy, Chief Financial Officer


+1 301-944-1660

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

Rupert Dearden



+44 (0)20 7886 2500

Joint Corporate Broker

Numis Securities Limited

James Black

Duncan Monteith 


+44 (0)20 7260 1000


Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh




+44 (0)203 709 5700


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
UK 100

Latest directors dealings